ZA200804301B - 1,5-substituted indol-2-yl amide derivatives - Google Patents

1,5-substituted indol-2-yl amide derivatives

Info

Publication number
ZA200804301B
ZA200804301B ZA200804301A ZA200804301A ZA200804301B ZA 200804301 B ZA200804301 B ZA 200804301B ZA 200804301 A ZA200804301 A ZA 200804301A ZA 200804301 A ZA200804301 A ZA 200804301A ZA 200804301 B ZA200804301 B ZA 200804301B
Authority
ZA
South Africa
Prior art keywords
amide derivatives
substituted indol
indol
substituted
amide
Prior art date
Application number
ZA200804301A
Other languages
English (en)
Inventor
Nettekoven Matthias
Plancher Jean-Marc
Richter Hans
Roche Olivier
Runtz-Schmitt Valerie
Taylor Sven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200804301(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200804301B publication Critical patent/ZA200804301B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200804301A 2005-11-30 2008-05-19 1,5-substituted indol-2-yl amide derivatives ZA200804301B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05111478 2005-11-30

Publications (1)

Publication Number Publication Date
ZA200804301B true ZA200804301B (en) 2009-04-29

Family

ID=37814240

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804301A ZA200804301B (en) 2005-11-30 2008-05-19 1,5-substituted indol-2-yl amide derivatives

Country Status (18)

Country Link
US (1) US7745479B2 (pt)
EP (1) EP1957479B1 (pt)
JP (1) JP4879997B2 (pt)
KR (1) KR101124156B1 (pt)
CN (1) CN101316840B (pt)
AR (1) AR057989A1 (pt)
AT (1) ATE500244T1 (pt)
AU (1) AU2006319234B2 (pt)
BR (1) BRPI0619268A2 (pt)
CA (1) CA2630314A1 (pt)
DE (1) DE602006020482D1 (pt)
ES (1) ES2359739T3 (pt)
IL (1) IL191314A (pt)
NO (1) NO20082136L (pt)
RU (1) RU2008126391A (pt)
TW (1) TWI333490B (pt)
WO (1) WO2007062999A2 (pt)
ZA (1) ZA200804301B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063000A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008083124A1 (en) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
JP5544296B2 (ja) * 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
JP5658138B2 (ja) * 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP6049615B2 (ja) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． ノリボガイン組成物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2851087C (en) * 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc PHOSPHATESTER OF NORIBOGAIN
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
PT3071203T (pt) 2013-11-18 2021-03-11 Forma Therapeutics Inc Composições de tetra-hidroquinolina como inibidores de bromodomínio bet
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
JP7230240B2 (ja) 2019-12-11 2023-02-28 富士フイルム株式会社 半月板投影面設定装置、方法およびプログラム
CN115340460B (zh) * 2022-09-21 2024-07-16 江西亚太科技发展有限公司 一种Reissert吲哚合成反应中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
BR9912980B1 (pt) 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1554260A1 (en) * 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
ES2306170T3 (es) 2004-06-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de indol como antagonistas redeptores de histamina.
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
JP4879997B2 (ja) 2012-02-22
KR101124156B1 (ko) 2012-03-23
US20070123515A1 (en) 2007-05-31
AU2006319234A1 (en) 2007-06-07
US7745479B2 (en) 2010-06-29
WO2007062999A2 (en) 2007-06-07
IL191314A (en) 2012-06-28
CN101316840B (zh) 2012-08-08
CN101316840A (zh) 2008-12-03
TW200804340A (en) 2008-01-16
AR057989A1 (es) 2008-01-09
KR20080076980A (ko) 2008-08-20
AU2006319234B2 (en) 2012-01-19
NO20082136L (no) 2008-06-30
ATE500244T1 (de) 2011-03-15
EP1957479A2 (en) 2008-08-20
CA2630314A1 (en) 2007-06-07
TWI333490B (en) 2010-11-21
RU2008126391A (ru) 2010-01-10
JP2009517433A (ja) 2009-04-30
EP1957479B1 (en) 2011-03-02
DE602006020482D1 (de) 2011-04-14
BRPI0619268A2 (pt) 2011-09-20
WO2007062999A3 (en) 2007-07-26
ES2359739T3 (es) 2011-05-26

Similar Documents

Publication Publication Date Title
ATE500244T1 (de) 1,5-substituierte indol-2-yl amidderivative
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IL211894A0 (en) Amide derivatives
IL183657A0 (en) Amide derivatives
GB0504019D0 (en) Amide derivatives
ZA200800920B (en) Amide derivatives
IL182538A0 (en) 1,5-diheterocycle-1h-triazole derivative
ZA200707933B (en) Substituted aryl 1.4-pyrazine derivatives
EP1830858A4 (en) 3,6-BICYCLOLIDE
IL184677A0 (en) Substituted 1,1,1-trifluoro-3-[(benzyl)-
PT1881830E (pt) Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexa-hidroquinolina para o tratamento da infertilidade
GB0425572D0 (en) 1,7-Naphthyridines
IL188111A0 (en) 2,5-bis-diamimne [1,4] benzoquinone-derivatives
GB0507114D0 (en) No 1 timemachine
IL186226A0 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
GB0509703D0 (en) Hayfit 2
GB0514559D0 (en) Qmaster 2005
ZA200705150B (en) Amide derivatives
GB0507513D0 (en) Amide derivatives
GB0526315D0 (en) Amide derivatives
GB0409804D0 (en) Amide derivatives
GB0409800D0 (en) Amide derivatives
GB0512288D0 (en) iCorcost 1
GB0512289D0 (en) iCorcost 4
GB0517452D0 (en) iCorcost 5